Leonard Frank X
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to Leonard Frank X. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| NVCR | EVP, Pres., Novocure Oncology | Tax Withholding | 966 | $12.81 | $12,374 | Nov 1, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Award / Grant | 833 | $15.13 | $12,603 | Jun 30, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Award / Grant | 179,426 | — | — | Jun 4, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 1,879 | $19.01 | $35,720 | Jun 2, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Award / Grant | 54,975 | $18.19 | $999,995 | Mar 4, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 2,527 | $18.54 | $46,851 | Mar 3, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 1,989 | $20.55 | $40,874 | Feb 28, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 1,989 | $20.55 | $40,874 | Feb 27, 2025 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 598 | $15.94 | $9,532 | Nov 1, 2024 |
| NVCR | EVP, Pres., Novocure Oncology | Award / Grant | 1,736 | $12.24 | $21,249 | Jun 28, 2024 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 840 | $16.01 | $13,448 | Mar 1, 2024 |
| NVCR | EVP, Pres., Novocure Oncology | Sale | 2,078 | $16.14 | $33,539 | Feb 27, 2024 |
| NVCR | President, CNS Cancers US | Sale | 4,403 | $76.16 | $335,332 | Mar 3, 2023 |
| NVCR | President, CNS Cancers US | Sale | 844 | $75.28 | $63,536 | Mar 3, 2023 |
| NVCR | President, CNS Cancers US | Sale | 308 | $76.05 | $23,423 | Mar 2, 2023 |
| NVCR | President, CNS Cancers US | Sale | 1,684 | $76.36 | $128,590 | Feb 28, 2023 |
| NVCR | President, CNS Cancers US | Sale | 526 | $115.03 | $60,506 | Jan 5, 2023 |
| NVCR | President, CNS Cancers US | Award / Grant | 6,830 | — | — | Nov 1, 2022 |
| NVCR | President, CNS Cancers US | Sale | 6,754 | $76.01 | $513,372 | Oct 13, 2022 |
| NVCR | President, CNS Cancers US | Sale | 6,754 | $84.37 | $569,835 | Oct 6, 2022 |
| NVCR | President, CNS Cancers US | Sale | 6,754 | $77.35 | $522,422 | Sep 29, 2022 |
| NVCR | President, CNS Cancers US | Sale | 6,754 | $77.00 | $520,058 | Sep 22, 2022 |
| NVCR | Chief Development Officer | Sale | 5,517 | $90.00 | $496,530 | Sep 15, 2022 |
| NVCR | Chief Development Officer | Sale | 1,863 | $88.00 | $163,944 | Sep 9, 2022 |
| NVCR | Chief Development Officer | Sale | 6,754 | $81.48 | $550,316 | Sep 8, 2022 |
| NVCR | Chief Development Officer | Sale | 1,384 | $78.57 | $108,741 | Sep 6, 2022 |
| NVCR | Chief Development Officer | Sale | 240 | $75.88 | $18,211 | Sep 1, 2022 |
| NVCR | Chief Development Officer | Sale | 414 | $69.66 | $28,839 | Aug 2, 2022 |
| NVCR | Chief Development Officer | Award / Grant | 312 | $59.08 | $18,433 | Jul 5, 2022 |
| NVCR | Chief Development Officer | Sale | 744 | $70.10 | $52,154 | Mar 8, 2022 |
| NVCR | Chief Development Officer | Sale | 930 | $74.50 | $69,285 | Mar 3, 2022 |
| NVCR | Chief Development Officer | Sale | 540 | $138.23 | $74,644 | Sep 2, 2021 |
| NVCR | Chief Development Officer | Sale | 328 | $149.43 | $49,013 | Aug 2, 2021 |
| NVCR | Chief Development Officer | Award / Grant | 154 | $137.12 | $21,116 | Jul 6, 2021 |
| NVCR | Chief Development Officer | Sale | 765 | $130.81 | $100,070 | Mar 8, 2021 |
| NVCR | Chief Development Officer | Sale | 567 | $137.55 | $77,991 | Mar 4, 2021 |
| NVCR | Chief Development Officer | Sale | 430 | $152.05 | $65,382 | Mar 2, 2021 |
| NVCR | Chief Development Officer | Option Exercise | 1,465 | $149.10 | $218,432 | Feb 27, 2021 |
| NVCR | Chief Development Officer | Award / Grant | 5,904 | — | — | Sep 1, 2020 |